Published in

PAGEpress, Mediterranean Journal of Hematology and Infectious Diseases, 1(5), p. e2013061, 2013

DOI: 10.4084/mjhid.2013.061

Links

Tools

Export citation

Search in Google Scholar

Tuberculosis in Hematopoietic Stem Cell Transplant Patients.

Journal article published in 2013 by Silvia F. Costa ORCID, Jessica Ramos, Marjorie Vieira Batista ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Description of tuberculosis (TB) among Hematopoietic Stem Cell Transplant (HSCT) recipients is scanty in the literature even in countries where TB is common. Most of reports of TB in HSCT patients were from ASIA, with TB incidence varying from 0.0014 (USA) to 16% (Pakistan). There are few reports of diagnosis of TB during the first two weeks after HSCT, most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most often involved. The mortality varied from 0 to 50% and is higher among allogeneic HSCT. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, and primary prophylaxis for latent TB, and whether in developing country with high prevalence of TB the epidemiologic query should be emphasized.